Fleury traded at 23.50 this Friday October 2nd, decreasing 0.25 or 1.05 percent since the previous trading session. Looking back, over the last four weeks, Fleury lost 16.92 percent. Over the last 12 months, its price rose by 46.88 percent. Looking ahead, we forecast Fleury to be priced at 22.81 by the end of this quarter and at 20.86 in one year, according to Trading Economics global macro models projections and analysts expectations.
Fleury SA is a Brazil-based company engaged in the provision of medical laboratory services. The Company’s activities are divided into three business lines: Patient Service Centers (PSC), B2B and Dental Diagnosis. The PCS division offers private medical diagnostics. The B2B division is responsible for clinical analysis and diagnostic imaging in partner hospitals, as well as tests for laboratories, hospitals and clinics throughout Brazil. The Dental Diagnosis division provides dental diagnostic imaging through Papaiz Associados Diagnosticos por Imagem SA, a joint venture with Odontoprev SA. The Company operates through several brands, such as Fleury Medicina e Saude, Clinica Felippe Mattoso e Weinmann, a+ Medicina Diagnostica, Diagnoson a+, Diagmax and Inlab, among others.